| Literature DB >> 34829990 |
Lijun Sun1, Shasha An1, Zhihao Zhang1, Yaling Zhou1, Yanan Yu1, Zhanke Ma1, Xiushan Fan1, Liang Tang1, Jianzhong Guo2.
Abstract
Low-intensity pulsed ultrasound (LIPUS) has been proved to promote the proliferation of myoblast C2C12. However, whether LIPUS can effectively prevent muscle atrophy has not been clarified, and if so, what is the possible mechanism. The aim of this study is to evaluate the effects of LIPUS on muscle atrophy in hindlimb unloading rats, and explore the mechanisms. The rats were randomly divided into four groups: normal control group (NC), hindlimb unloading group (UL), hindlimb unloading plus 30 mW/cm2 LIPUS irradiation group (UL + 30 mW/cm2), hindlimb unloading plus 80 mW/cm2 LIPUS irradiation group (UL + 80 mW/cm2). The tails of rats in hindlimb unloading group were suspended for 28 days. The rats in the LIPUS treated group were simultaneously irradiated with LIPUS on gastrocnemius muscle in both lower legs at the sound intensity of 30 mW/cm2 or 80 mW/cm2 for 20 min/d for 28 days. C2C12 cells were exposed to LIPUS at 30 or 80 mW/cm2 for 5 days. The results showed that LIPUS significantly promoted the proliferation and differentiation of myoblast C2C12, and prevented the decrease of cross-sectional area of muscle fiber and gastrocnemius mass in hindlimb unloading rats. LIPUS also significantly down regulated the expression of MSTN and its receptors ActRIIB, and up-regulated the expression of Akt and mTOR in gastrocnemius muscle of hindlimb unloading rats. In addition, three metabolic pathways (phenylalanine, tyrosine and tryptophan biosynthesis; alanine, aspartate and glutamate metabolism; glycine, serine and threonine metabolism) were selected as important metabolic pathways for hindlimb unloading effect. However, LIPUS promoted the stability of alanine, aspartate and glutamate metabolism pathway. These results suggest that the key mechanism of LIPUS in preventing muscle atrophy induced by hindlimb unloading may be related to promoting protein synthesis through MSTN/Akt/mTOR signaling pathway and stabilizing alanine, aspartate and glutamate metabolism.Entities:
Keywords: low intensity pulsed ultrasound; metabonomics; muscle atrophy; myostatin
Mesh:
Substances:
Year: 2021 PMID: 34829990 PMCID: PMC8625684 DOI: 10.3390/ijms222212112
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1(A) Body weight. (B) Gastrocnemius muscle weight. The data were expressed as mean ± SD (n = 8 in each group), ** p < 0.01 vs. NC group, * p < 0.05 vs. NC group, # p < 0.05 vs. UL group.
Figure 2(A) The average cross-sectional area of fast muscle fibers. (B) The average cross-sectional area of slow muscle fibers. (C) The mean area of gastrocnemius muscle fiber. The data were expressed as mean ± SD (n = 8 in each group), ** p < 0.01 vs. NC group, ## p < 0.01 vs. UL group, # p < 0.05 vs. UL group.
Figure 3(A) The gastrocnemius force generation stimulated at 30, 50 and 80 Hz. (B) The gastrocnemius force generation stimulated at 50 Hz. The data were expressed as mean ± SD (n = 8 in each group), ** p < 0.01 vs. NC group.
Figure 4(A) DAPI staining of myoblasts C2C12 stimulated by LIPUS at different intensities. (B) The proliferation of C2C12 myoblasts. (C) The number of nuclei of C2C12 myoblasts. The data were expressed as mean ± SD (n = 8 in each group), ** p < 0.01 vs. NC group, * p < 0.05 vs. NC group, ## p < 0.01 vs. LIPUS-30 mW/cm2group, # p < 0.05 vs. 30 mW/cm2 group.
Figure 5(A) HE staining of C2C12 after LIPUS irradiation with different intensities. (B) FITC-phalloidin labeled microfilament immunofluorescence staining. (C) MyHC3 protein expression of C2C12. (A(a)) The number of myotubes in HE staining (n = 8 in each group). (B(b)) The cell length/width ratio in microfilament staining (n = 3 in each group). ** p < 0.01 vs. NC group, ## p < 0.01 vs. LIPUS-30 mW/cm2 group.
Figure 6(A) The mRNA level of MSTN in gastrocnemius muscle. (B) The mRNA level of ActrΙΙB in gastrocnemius muscle. (C) The protein level of MSTN in gastrocnemius muscle. (D) The protein level of ActrΙΙB in gastrocnemius muscle. (E)The protein level of AKT in gastrocnemius muscle. (F) The protein level of mTOR in gastrocnemius muscle. The data were expressed as mean ± SD (n = 3 in each group), ** p < 0.01 vs. NC group, * p < 0.05 vs. NC group, ## p < 0.01 vs. UL group, # p < 0.05 vs. UL group, @@ p < 0.01 vs. 30 mW/cm2 group, @ p < 0.05 vs. 30 mW/cm2 group.
Figure 7(A) Blood total ion flow diagram of NC and UL groups. (B) Blood total ion of UL and 30 mW/cm2 LIPUS groups. (C) Blood total ion flow diagram of UL and 80 mW/cm2 LIPUS groups. (D) PCA score of UL and NC group. (E) PCA score of UL and 30 mW/cm2 LIPUS groups. (F) PCA score of UL and 80 mW/cm2 LIPUS groups. (G) The OPLS-DA score of UL and NC rats. (H) The OPLS-DA score chart of UL and 30 mW/cm2 LIPUS groups. (I) The OPLS-DA score of UL and 80 mW/cm2 LIPUS groups was compared. (J) Validation of OPLS-DA model of rats blood samples from four groups by permutation test (the x-axis means the correlation coefficient between the original y variable and the permutated y variable and the y-axis is the value of R2 and Q2).
Potential biomarkers and the relatedpathways.
| Comparison | No. | RT | m/z | KEGG | Formula | Metabolite | Trend | Related Pathway |
|---|---|---|---|---|---|---|---|---|
| UL vs. NC | 1 | 6.387 | 147.050 | C00041 | C3H7NO2 | Alanine | ↓ * | Alanine, aspartate and glutamate metabolism; |
| 2 | 9.490 | 149.050 | C00042 | C4H6O4 | Succinic acid | ↓ * | TCA cycle; oxidative phosphorylation; | |
| 3 | 10.985 | 130.050 | C00049 | C4H7NO4 | L-Aspartic acid | ↓ * | Alanine, aspartate and glutamate metabolism; | |
| 4 | 8.720 | 132.050 | C00065 | C3H7NO3 | L-Serine | ↓ ** | Glycine, serine and threonine metabolism; | |
| 5 | 16.436 | 179.050 | C00082 | C9H11NO3 | Tyrosine | ↓ * | Phenylalanine, tyrosine and tryptophan biosynthesis; phenylalanine metabolism | |
| 6 | 8.495 | 189.050 | C00086 | CH4N2O | Urea | ↓ ** | Arginine and proline metabolism | |
| 7 | 7.168 | 86.150 | C00123 | C6H13NO2 | L-Leucine | ↓ ** | valine, leucine and isoleucine degradation; | |
| 8 | 19.307 | 147.050 | C00137 | C6H12O6 | Myo-Inositol | ↓ * | Galactose metabolism | |
| 9 | 15.779 | 73.050 | C00158 | C6H8O7 | Citric acid | ↓ * | TCA cycle | |
| 10 | 6.112 | 72.150 | C00183 | C5H11NO2 | L-Valine | ↓ ** | ABC transporters; | |
| 11 | 5.748 | 106.050 | C00186 | C3H6O3 | Lactic acid | ↓ ** | Gluconeogenesis; | |
| 12 | 33.925 | 329.350 | C00187 | C27H46O | Cholesterol | ↓ * | Steroid biosynthesis; | |
| UL | 1 | 10.985 | 130.050 | C00049 | C4H7NO4 | L-Aspartic acid | ↑ ** | Alanine, aspartate and glutamate metabolism; arginine and proline metabolism |
| 2 | 8.509 | 73.050 | C00086 | CH4N2O | Urea | ↑ * | Arginine and proline metabolism | |
| 3 | 86.150 | 7.168 | C00123 | C6H13NO2 | L-Leucine | ↑ ** | Valine, leucine and isoleucine degradation; | |
| 4 | 226.150 | 19.338 | C00137 | C6H12O6 | Myo-Inositol | ↑ ** | Galactose metabolism | |
| 5 | 73.050 | 15.779 | C00158 | C6H8O7 | Citric acid | ↑ ** | TCA cycle | |
| 6 | 6.112 | 72.150 | C00183 | C5H11NO2 | L-Valine | ↑ ** | ABC transporters; | |
| 7 | 33.920 | 129.050 | C00187 | C27H46O | Cholesterol | ↑ * | Steroid biosynthesis; | |
| 8 | 18.290 | 154.150 | C00249 | C16H32O2 | Palmitic Acid | ↑ *** | Fatty acid biosynthesis; | |
| 9 | 9.837 | 89.050 | C00258 | C3H6O4 | Glyceric acid | ↓ * | Glycine, serine and threonine metabolism | |
| 10 | 14.597 | 73.050 | C00379 | C5H12O5 | Xylitol | ↑ * | Pentose and glucuronate interconversions | |
| UL | 1 | 14.597 | 73.050 | C00049 | C4H7NO4 | Xylitol | ↑ * | Alanine, aspartate and glutamate metabolism; arginine and proline metabolism |
| 2 | 10.985 | 130.05 | C00065 | C3H7NO3 | L-Aspartic acid | ↑ * | Glycine, serine and threonine metabolism; sphingolipid metabolism | |
| 3 | 8.711 | 116.05 | C00086 | CH4N2O | L-Serine | ↑ * | Arginine and proline metabolism | |
| 4 | 8.506 | 137.05 | C00123 | C6H13NO2 | Urea | ↑ *** | Valine, leucine and isoleucine degradation; | |
| 5 | 7.168 | 86.15 | C00137 | C6H12O6 | L-Leucine | ↑ * | Galactose metabolism | |
| 6 | 19.307 | 217.15 | C00158 | C6H8O7 | Myo-Inositol | ↑ * | TCA cycle | |
| 7 | 15.779 | 73.05 | C00186 | C3H6O3 | Citric acid | ↑ * | Gluconeogenesis; | |
| 8 | 5.742 | 6 | C00187 | C27H46O | Lactic acid | ↑ * | Steroid biosynthesis; | |
| 9 | 33.92 | 129.05 | C00188 | C4H9NO3 | Cholesterol | ↑ * | Valine, leucine and isoleucine biosynthesis; aminoacyl-tRNA biosynthesis | |
| 10 | 9.245 | 117.05 | C00249 | C16H32O2 | L-Threonine | ↑ * | Fatty acid biosynthesis; | |
| 11 | 9.807 | 133.050 | C00258 | C3H6O4 | Glyceric acid | ↑ * | Glycine, serine and threonine metabolism | |
| 12 | 18.287 | 133.05 | C00249 | C16H32O2 | Palmitic Acid | ↑ ** | Fatty acid metabolism | |
| 13 | 6.116 | 55.15 | C00183 | C5H11NO2 | L-Valine | ↑ * | ABC transporters; |
* p < 0.05 and ** p < 0.01, *** p < 0.001.
Figure 8(A) Differential metabolic pathways between NC and UL groups. The color (light to dark) of the point represents the p value (Y-axis), and the size of the point represents the metabolic pathway impact (X-axis). (A(a)): phenylalanine, tyrosine and tryptophan biosynthesis; (A(b)): alanine, aspartate and glutamate metabolism; (A(c)): glycine, serine and threonine metabolism. * p < 0.05 vs. NC group, ** p < 0.01 vs. NC group.
Figure 9(A) Differential metabolic pathway between UL and 30mW/cm2 LIPUS groups. The color (light to dark) of the point represents the p value (Y-axis), and the size of the point represents the metabolic pathway impact (X-axis). (A(b)): alanine, aspartate and glutamate metabolism; ** p < 0.01 vs. UL group.
Figure 10(A) Differential metabolic pathways between UL and 80 mW/cm2 groups. The color (light to dark) of the point represents the p value (Y-axis), and the size of the point represents the metabolic pathway impact (X-axis). (A(b)): alanine, aspartate and glutamate metabolism; (A(c)): glycine, serine and threonine metabolism. * p < 0.05 vs. UL group, ** p < 0.01 vs. UL group.